AB 1288: Health care coverage: Medication-assisted treatment.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2023-09-11
Current Status:
Failed
(2024-01-25: Consideration of Governor's veto stricken from file.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law, the KnoxKeene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law authorizes health care service plans and health insurers that cover prescription drugs to utilize reasonable medical management practices, including prior authorization and step therapy, consistent with applicable law.
This bill would prohibit a medical service plan and a health insurer from subjecting a naloxone product, or another opioid antagonist approved by the United States Food and Drug Administration, a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder to prior authorization or step therapy. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the KnoxKeene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law authorizes health care service plans and health insurers that cover prescription drugs to utilize reasonable medical management practices, including prior authorization and step therapy, consistent with applicable law.
This bill would prohibit a medical service plan and a health insurer from subjecting a naloxone product, or another opioid antagonist approved by the United States Food and Drug Administration, a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder to prior authorization or step therapy. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the KnoxKeene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law authorizes health care service plans and health insurers that cover prescription drugs to utilize reasonable medical management practices, including prior authorization and step therapy, consistent with applicable law.
This bill would prohibit a medical service plan and a health insurer from subjecting a naloxone product, buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder that is prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder to prior authorization. to prior authorization or step therapy. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the KnoxKeene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law authorizes health care service plans and health insurers that cover prescription drugs to utilize reasonable medical management practices, including prior authorization and step therapy, consistent with applicable law.
This bill would prohibit a medical service plan and a health insurer from subjecting a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder that is prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder to prior authorization. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Notwithstanding any other law, a health care service plan shall not subject any of the following to prior authorization or step therapy:
(a)A naloxone product or another opioid antagonist approved by the United States Food and Drug Administration.
(b)A buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder.
SEC. 2.Section 10123.1934 is added to the Insurance Code, to read:10123.1934.Notwithstanding any other law, a health insurer shall not subject any of the following to prior authorization or step therapy:
(a)A naloxone product or another opioid antagonist approved by the United States Food and Drug Administration.
(b)A buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
Notwithstanding any other law, a health care service plan shall not subject a naloxone product, any of the following to prior authorization or step therapy:
(a)A naloxone product or another opioid antagonist approved by the United States Food and Drug Administration.
(b)A buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder to prior authorization or step therapy. disorder.
SEC. 2.Section 10123.1934 is added to the Insurance Code, to read:10123.1934.Notwithstanding any other law, a health insurer shall not subject a naloxone product, any of the following to prior authorization or step therapy:
(a)A naloxone product or another opioid antagonist approved by the United States Food and Drug Administration.
(b)A buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder to prior authorization or step therapy. disorder.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
Notwithstanding any other law, a health care service plan shall not subject, a subject a naloxone product, buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder to prior authorization. to prior authorization or step therapy.
SEC. 2.Section 10123.1934 is added to the Insurance Code, to read:10123.1934.Notwithstanding any other law, a health insurer shall not subject a naloxone product, buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder to prior authorization. to prior authorization or step therapy.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
Notwithstanding any other law, a health care service plan shall not subject, a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder to prior authorization.
SEC. 2.Section 10123.1934 is added to the Insurance Code, to read:10123.1934.Notwithstanding any other law, a health insurer shall not subject a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder to prior authorization.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Jan 25, 2024 | Consideration of Governor's veto stricken from file. |
| Jan 3, 2024 | Consideration of Governor's veto pending. |
| Oct 8, 2023 | Vetoed by Governor. |
| Sep 14, 2023 | Enrolled and presented to the Governor at 4:30 p.m. |
| Sep 7, 2023 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 76. Noes 1. Page 3029.). |
| Sep 5, 2023 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after September 7 pursuant to Assembly Rule 77. |
| Sep 5, 2023 | Read third time. Passed. Ordered to the Assembly. (Ayes 36. Noes 0. Page 2374.). |
| Aug 16, 2023 | Read second time. Ordered to third reading. |
| Aug 15, 2023 | From committee: Do pass. (Ayes 5. Noes 0.) (August 14). |
| Jul 13, 2023 | Read second time and amended. Re-referred to Com. on APPR. |
| Jul 13, 2023 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 10. Noes 0.) (July 12). |
| Jul 5, 2023 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| Jun 19, 2023 | In committee: Hearing postponed by committee. |
| Jun 12, 2023 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| May 31, 2023 | Referred to Com. on HEALTH. |
| May 18, 2023 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 18, 2023 | Read third time. Passed. Ordered to the Senate. (Ayes 68. Noes 1. Page 1590.) |
| May 11, 2023 | Read second time. Ordered to third reading. |
| May 10, 2023 | From committee: Do pass. (Ayes 14. Noes 1.) (May 10). |
| Apr 26, 2023 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 14. Noes 1.) (April 25). Re-referred to Com. on APPR. |
| Mar 2, 2023 | Referred to Com. on HEALTH. |
| Feb 17, 2023 | From printer. May be heard in committee March 19. |
| Feb 16, 2023 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 7, 2023 | AB 1288 Rendon Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Sep 5, 2023 | Assembly 3rd Reading AB1288 Rendon et al. By Wiener | Senate Floor |
Passed |
|
| Aug 14, 2023 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Jul 12, 2023 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 18, 2023 | AB 1288 Reyes Assembly Third Reading | Assembly Floor |
Passed |
|
| May 10, 2023 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 25, 2023 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Alameda-Contra Costa Medical Association | ** Support | |
| Alkermes, Inc. | ** Support | |
| AmericaS Health Insurance Plans | ** Against | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| California Academy Of Family Physicians | ** Support | |
| California Association Of Family Physicians | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Health+Advocates | ** Support | |
| California Life Sciences | ** Support | |
| California Society Of Addiction Medicine | ** Support | |
| California State Association of Psychiatrists | ** Support | |
| Connection Coalition | ** Support | |
| County Behavioral Health Directors Association of California | ** Support | |
| National Health Law Program | ** Support | |
| Steinberg Institute | ** Support |
GOVERNOR'S VETO
GV Bill Id:AB 1288
Author:(Rendon)
As Enrolled Ver:September 11, 2023
2/3 vote
SUMMARY
Prohibits a health plan and a health insurer from requiring prior authorization for a naloxone product or another opioid antagonist approved by the United States Food and Drug Administration (FDA), a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder (SUD).
Senate Amendments
Specify that a naloxone product or another opioid antagonist is included in the above prohibition and delete the requirement that the above be prescribed according to generally accepted national professional guidelines for the treatment of a SUD to prior authorization.
Governor’s Veto Message
This bill would prohibit health plans from requiring prior authorization or step therapy for a naloxone product or other opioid antagonist approved by the FDA, buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or treatment of a SUD.
I appreciate the author's intent to increase access to medication for opioid use disorder (OUD). My Administration takes the opioid crisis seriously, as evidenced by the over $1 billion invested to combat overdoses, support those with opioid use disorder, raise awareness, and crack down on trafficking. However, utilization review is an important tool to contain health care costs, protect patients from unanticipated billing, and ensure medically necessary care. While immediacy of treatment is important, prior authorization also helps avoid fraudulent requests or abuse of the drugs addressed in this bill, such as methadone.
COMMENTS
According to the California Health Benefits Review Program (CHBRP), the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defines OUD as "a problematic pattern of opioid use leading to clinically significant impairment or distress" and persons must meet at least two of the defined criteria within a 12-month period to receive a diagnosis. OUD applies to the class of medications or drugs that includes illegal drugs such as heroin, synthetic opioids such as fentanyl, and prescription pain medications such as oxycodone, hydrocodone, codeine, and morphine that are misused for indications other than prescribed. Prescription opioids are used to treat moderate to severe pain, and persons who take prescription opioids can develop opioid use disorder.
The DSM-5 characterizes alcohol use disorder as a pattern of alcohol use (e.g., wine, beer, and spirits) that results in significant impairment or distress. People meeting at least two of 11 specified criteria within a 12-month period are diagnosed with mild, moderate, or severe alcohol use disorder depending on the number of criteria met.
OUD prevalence in California was 1.58% among people aged 12 years and older in 2021. In the United States, among those reporting a prescription opioid use disorder, 35.2% also report alcohol use disorder. Alcohol use disorder prevalence in California was 11% among people aged 12 or older in 2021. In the United States, among those reporting alcohol use disorder, 3.9% report a related prescription opioid use disorder. In 2017, the U.S. Surgeon General declared the opioid crisis a U.S. public health emergency due to the escalating rates of opioid overdose, and related mortality and other harms. In addition to a greater risk of mortality and premature mortality, people with opioid use disorder are at a higher risk for developing cardiac dysrhythmias; respiratory depression; impairment in daily function; and contraction of infections including HIV, hepatitis (A, B, and C), tuberculosis, and endocarditis, which lead to increased use of health care services to treat those conditions.
The Substance Abuse and Mental Health Services Administration (SAMHSA) describes maintenance treatment as "providing medications to achieve and sustain clinical remission of signs and symptoms of OUD and support the individual process of recovery without a specific endpoint." Some persons with OUD may require long-term medication treatment to ensure sustained recovery. There is evidence that relapse of OUD occurs less often for patients on medications (buprenorphine-naloxone and long-acting injectable naltrexone) for treatment (16%) compared to patients with no medication for treatment (40%). Some persons with alcohol use disorder experience a chronic condition with recurring treatment, abstinence, and relapse. Data from a nationally representative sample from 2012 to 2013 found that one third of adults with alcohol use disorder prior to the past year still had persistent alcohol use disorder, over half had remission from alcohol use disorder as classified by the DSM-5, and of the respondents that met criteria for remission, one third were indicative of recovery.
- Opioid Related Overdose Deaths in California. The Department of Public Health reports on its Opioid Overdose Death Dashboard that in 2021, there were 7,175 opioid related deaths in California. Of those over 83% involved fentanyl, a potent synthetic opioid drug that is approximately 50 times stronger than heroin and 100 times stronger than morphine. The number of deaths each year involving fentanyl increased dramatically between 2012 and 2021. During this time period fentanyl related overdose deaths increased by more than 7,250% -- from 82 deaths to 5,961 deaths in 2021.
In 2019, almost one third of white persons with opioid use disorder received medications for treatment compared to 20% of Black or other non-Latino multiracial groups and 15% of Latino persons. Prescribing practices changed significantly for medications prescribed for OUD (buprenorphine and long-acting injectable naltrexone) after the beginning of the COVID-19 pandemic, with 30.5% decrease for buprenorphine and 10.5% decrease of long-acting injectable naltrexone across all races/ethnicities. However, Black, Latino, and Asian persons experienced greater decreases in buprenorphine prescription fills compared to white persons. Racial disparities in overdoses have emerged with greater increases among Black and Latino persons. In California, the opioid-related overdose death rate was highest among American Indian/Alaskan Native and Black persons compared to white persons and healthcare utilization for opioid-related overdoses in the emergency department and hospitalization was highest among Black persons during 2021.
- Medication-assisted treatment (MAT). Treatments for SUD include prescription medication (medications for OUD or medications for alcohol use disorder), also called MAT, as well as counseling, residential facilities, and mutual help groups (e.g., Alcoholics Anonymous, Narcotics Anonymous). This bill lists three FDA-approved MAT options for OUD and alcohol use disorder: buprenorphine products, methadone, or long-acting injectable naltrexone. Methadone as a treatment for OUD is only available from opioid treatment programs (OTPs). Rules governing OTPs exist at both the federal and state levels: The federal government establishes baseline requirements for OTPs, and states layer additional requirements on top of them. The American Society of Addiction Medicine (ASAM) provides the National Practice Guidelines for the Use of Medications in the Treatment of Addiction Involving Opioid Use and SAMHSA provides the Treatment Improvement Protocol that reviews the clinical standards of care for patients with OUD including buprenorphine, methadone, and long-acting injectable naltrexone. In 2020, the ASAM updated requirements to include that all FDA approved medication prescribed for the treatment of OUD should be available to all persons seeking treatment.
- CHBRP analysis. CHBRP states the following in its analysis of this bill:
- Impact on utilization and expenditures. According to CHBRP, no measurable change in utilization or expenditures at the state level is expected because benefit coverage would change for very few commercial/CalPERS enrollees (1% to 5% of depending on the medication) and few in that group would both have one of the disorders and be a likely user of one of the medications. However, it is possible that a few enrollees might increase utilization of the medications addressed by this bill, postmandate.
- Medical effectiveness. There is limited evidence that removal of prior authorization requirements for buprenorphine products is associated with increased use and higher treatment retention for OUD. There is insufficient evidence on the impact of prior authorization on methadone use for OUD. There is insufficient evidence on the impact of prior authorization on long-acting injectable naltrexone use for either OUD or alcohol use disorder. For treatment of OUD, there is clear and convincing evidence that buprenorphine products and methadone are more effective with regard to treatment retention, reduction in use of illicit opioids, relapse, and improved health outcomes, compared to a placebo or no treatment. There is a preponderance of evidence that long-acting injectable naltrexone is effective with regard to treatment retention and abstinence, but not for overdose prevention, compared to a placebo or oral naltrexone. For treatment of alcohol use disorder, there is a preponderance of evidence that long-acting injectable naltrexone is more effective with regard to reducing return to drinking compared to a placebo or oral naltrexone.
According to the Author
There is an urgent need to expand access to rapid initiation of medications to treat addiction. This bill expands on the recent work of the federal government to mainstream addiction treatment by eliminating unnecessary barriers to treatment. As a policy, commercially insured Californians are the only group where prior authorization delays are still allowed. The author concludes that by removing this last barrier this bill will expand low barrier treatment options for at risk patients, prevent overdose and save lives.
Arguments in Support
National Health Law Program (NHLP) writes that for the past several years, California has made concerted efforts to increase access to MAT. One of these efforts has been ensuring that health plans across the state provide comprehensive coverage for all FDA-approved medications to treat OUD. As a result, both Medi-Cal and private health plans now offer coverage for methadone, buprenorphine, and naltrexone, as well as for services associated with effective use of these medications, such as ordering, prescribing, administering, and counseling. Despite these gains, however, many private plans continue to sidestep their responsibility to cover MAT by imposing utilization controls that only serve to reduce the costs to the plan, while establishing barriers to care and putting the lives of people with OUD at risk. The most commonly used of these utilization control techniques is prior authorization, an onerous requirement that delays access to lifesaving services without any significant benefit to the patient. Imposing prior authorization on MAT may also represent a violation of federal behavioral health parity requirements if it is applied disproportionately to MAT and other SUD treatment over physical health services. Given how beneficial MAT is for patients with OUD, California must ensure that patients can access the service without delay. NHLP states that prohibiting plans from imposing prior authorization is an important and essential step in that direction.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. The opposition states mandate bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options.
FISCAL COMMENTS
According to the Senate Appropriations Committee, the Department of Managed Health Care estimates costs of approximately $64,000 in 2024-25 and $133,000 in 2025-26 and annually thereafter for state administration (Managed Care Fund). The California Department of Insurance estimates costs of $3,000 in 2023-24 for state administration (Insurance Fund).
VOTES
ASM HEALTH: 14-1-0
YES: Wood, Waldron, Aguiar-Curry, Arambula, Boerner, Wendy Carrillo, Vince Fong, Maienschein, McCarty, Joe Patterson, Rodriguez, Santiago, Villapudua, Weber
NO: Flora
ASM APPROPRIATIONS: 14-1-1
YES: Holden, Megan Dahle, Bryan, Calderon, Wendy Carrillo, Mike Fong, Addis, Lowenthal, Papan, Pellerin, Robert Rivas, Sanchez, Weber, Wilson
NO: Dixon
ABS, ABST OR NV: Mathis
ASSEMBLY FLOOR: 68-1-11
YES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Chen, Connolly, Megan Dahle, Davies, Mike Fong, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Wallis, Ward, Weber, Wicks, Wood, Zbur, Rendon
NO: Dixon
ABS, ABST OR NV: Cervantes, Essayli, Flora, Vince Fong, Friedman, Gallagher, Mathis, Jim Patterson, Ta, Waldron, Wilson
SENATE FLOOR: 37-0-3
YES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Caballero, Cortese, Dahle, Dodd, Durazo, Eggman, Glazer, Gonzalez, Grove, Hurtado, Jones, Laird, Limón, McGuire, Menjivar, Min, Newman, Niello, Ochoa Bogh, Portantino, Roth, Rubio, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
ABS, ABST OR NV: Nguyen, Padilla, Seyarto
ASSEMBLY FLOOR: 76-1-3
YES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Chen, Connolly, Megan Dahle, Davies, Flora, Mike Fong, Vince Fong, Friedman, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, Mathis, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Luz Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NO: Dixon
ABS, ABST OR NV: Essayli, Jim Patterson, Ta
UPDATED
VERSION: September 11, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0002508
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 1288
Author:(Rendon)
As Amended Ver:July 13, 2023
Majority vote
SUMMARY
Prohibits a health plan and a health insurer from requiring prior authorization for a naloxone product or another opioid antagonist approved by the United States Food and Drug Administration (FDA), a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder (SUD).
Senate Amendments
Specify that a naloxone product or another opioid antagonist is included in the above prohibition and delete the requirement that the above be prescribed according to generally accepted national professional guidelines for the treatment of a SUD to prior authorization.
COMMENTS
This bill prohibits health plans and insurance policies from requiring prior authorization for a naloxone product or another opioid antagonist, buprenorphine products, methadone, or long-acting injectable naltrexone for detoxification (medically supervised withdrawal) or maintenance treatment of a SUD that is prescribed according to generally accepted national professional guidelines for the treatment of an SUD. According to the California Health Benefits Review Program (CHBRP), the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defines opioid use disorder (OUD) as "a problematic pattern of opioid use leading to clinically significant impairment or distress" and persons must meet at least two of the defined criteria within a 12-month period to receive a diagnosis. OUD applies to the class of medications or drugs that includes illegal drugs such as heroin, synthetic opioids such as fentanyl, and prescription pain medications such as oxycodone, hydrocodone, codeine, and morphine that are misused for indications other than prescribed. Prescription opioids are used to treat moderate to severe pain, and persons who take prescription opioids can develop opioid use disorder.
The DSM-5 characterizes alcohol use disorder as a pattern of alcohol use (e.g., wine, beer, and spirits) that results in significant impairment or distress. People meeting at least two of 11 specified criteria within a 12-month period are diagnosed with mild, moderate, or severe alcohol use disorder depending on the number of criteria met.
OUD prevalence in California was 1.58% among people aged 12 years and older in 2021. In the United States, among those reporting a prescription opioid use disorder, 35.2% also report alcohol use disorder. Alcohol use disorder prevalence in California was 11% among people aged 12 or older in 2021. In the United States, among those reporting alcohol use disorder, 3.9% report a related prescription opioid use disorder. In 2017, the U.S. Surgeon General declared the opioid crisis a U.S. public health emergency due to the escalating rates of opioid overdose, and related mortality and other harms. In addition to a greater risk of mortality and premature mortality, people with opioid use disorder are at a higher risk for developing cardiac dysrhythmias; respiratory depression; impairment in daily function; and contraction of infections including HIV, hepatitis (A, B, and C), tuberculosis, and endocarditis, which lead to increased use of health care services to treat those conditions.
The Substance Abuse and Mental Health Services Administration (SAMHSA) describes maintenance treatment as "providing medications to achieve and sustain clinical remission of signs and symptoms of OUD and support the individual process of recovery without a specific endpoint." Some persons with OUD may require long-term medication treatment to ensure sustained recovery. There is evidence that relapse of OUD occurs less often for patients on medications (buprenorphine-naloxone and long-acting injectable naltrexone) for treatment (16%) compared to patients with no medication for treatment (40%). Some persons with alcohol use disorder experience a chronic condition with recurring treatment, abstinence, and relapse. Data from a nationally representative sample from 2012 to 2013 found that one third of adults with alcohol use disorder prior to the past year still had persistent alcohol use disorder, over half had remission from alcohol use disorder as classified by the DSM-5, and of the respondents that met criteria for remission, one third were indicative of recovery.
- Opioid Related Overdose Deaths in California. The Department of Public Health reports on its Opioid Overdose Death Dashboard that in 2021, there were 7,175 opioid related deaths in California. Of those over 83% involved fentanyl, a potent synthetic opioid drug that is approximately 50 times stronger than heroin and 100 times stronger than morphine. The number of deaths each year involving fentanyl increased dramatically between 2012 and 2021. During this time period fentanyl related overdose deaths increased by more than 7,250% -- from 82 deaths to 5,961 deaths in 2021.
In 2019, almost one third of white persons with opioid use disorder received medications for treatment compared to 20% of Black or other non-Latino multiracial groups and 15% of Latino persons. Prescribing practices changed significantly for medications prescribed for OUD (buprenorphine and long-acting injectable naltrexone) after the beginning of the COVID-19 pandemic, with 30.5% decrease for buprenorphine and 10.5% decrease of long-acting injectable naltrexone across all races/ethnicities. However, Black, Latino, and Asian persons experienced greater decreases in buprenorphine prescription fills compared to white persons. Racial disparities in overdoses have emerged with greater increases among Black and Latino persons. In California, the opioid-related overdose death rate was highest among American Indian/Alaskan Native and Black persons compared to white persons and healthcare utilization for opioid-related overdoses in the emergency department and hospitalization was highest among Black persons during 2021.
- Medication-assisted treatment (MAT). Treatments for SUD include prescription medication (medications for OUD or medications for alcohol use disorder), also called MAT, as well as counseling, residential facilities, and mutual help groups (e.g., Alcoholics Anonymous, Narcotics Anonymous). This bill lists three FDA-approved MAT options for OUD and alcohol use disorder: buprenorphine products, methadone, or long-acting injectable naltrexone. Methadone as a treatment for OUD is only available from opioid treatment programs (OTPs). Rules governing OTPs exist at both the federal and state levels: The federal government establishes baseline requirements for OTPs, and states layer additional requirements on top of them. The American Society of Addiction Medicine (ASAM) provides the National Practice Guidelines for the Use of Medications in the Treatment of Addiction Involving Opioid Use and SAMHSA provides the Treatment Improvement Protocol that reviews the clinical standards of care for patients with OUD including buprenorphine, methadone, and long-acting injectable naltrexone. In 2020, the ASAM updated requirements to include that all FDA approved medication prescribed for the treatment of OUD should be available to all persons seeking treatment.
- CHBRP analysis. CHBRP states the following in its analysis of this bill:
- Impact on utilization and expenditures. According to CHBRP, no measurable change in utilization or expenditures at the state level is expected because benefit coverage would change for very few commercial/CalPERS enrollees (1% to 5% of depending on the medication) and few in that group would both have one of the disorders and be a likely user of one of the medications. However, it is possible that a few enrollees might increase utilization of the medications addressed by this bill, postmandate.
- Medical effectiveness. There is limited evidence that removal of prior authorization requirements for buprenorphine products is associated with increased use and higher treatment retention for OUD. There is insufficient evidence on the impact of prior authorization on methadone use for OUD. There is insufficient evidence on the impact of prior authorization on long-acting injectable naltrexone use for either OUD or alcohol use disorder. For treatment of OUD, there is clear and convincing evidence that buprenorphine products and methadone are more effective with regard to treatment retention, reduction in use of illicit opioids, relapse, and improved health outcomes, compared to a placebo or no treatment. There is a preponderance of evidence that long-acting injectable naltrexone is effective with regard to treatment retention and abstinence, but not for overdose prevention, compared to a placebo or oral naltrexone. For treatment of alcohol use disorder, there is a preponderance of evidence that long-acting injectable naltrexone is more effective with regard to reducing return to drinking compared to a placebo or oral naltrexone.
According to the Author
There is an urgent need to expand access to rapid initiation of medications to treat addiction. This bill expands on the recent work of the federal government to mainstream addiction treatment by eliminating unnecessary barriers to treatment. As a policy, commercially insured Californians are the only group where prior authorization delays are still allowed. The author concludes that by removing this last barrier this bill will expand low barrier treatment options for at risk patients, prevent overdose and save lives.
Arguments in Support
National Health Law Program (NHLP) writes that for the past several years, California has made concerted efforts to increase access to MAT. One of these efforts has been ensuring that health plans across the state provide comprehensive coverage for all FDA-approved medications to treat OUD. As a result, both Medi-Cal and private health plans now offer coverage for methadone, buprenorphine, and naltrexone, as well as for services associated with effective use of these medications, such as ordering, prescribing, administering, and counseling. Despite these gains, however, many private plans continue to sidestep their responsibility to cover MAT by imposing utilization controls that only serve to reduce the costs to the plan, while establishing barriers to care and putting the lives of people with OUD at risk. The most commonly used of these utilization control techniques is prior authorization, an onerous requirement that delays access to lifesaving services without any significant benefit to the patient. Imposing prior authorization on MAT may also represent a violation of federal behavioral health parity requirements if it is applied disproportionately to MAT and other SUD treatment over physical health services. Given how beneficial MAT is for patients with OUD, California must ensure that patients can access the service without delay. NHLP states that prohibiting plans from imposing prior authorization is an important and essential step in that direction.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. The opposition states mandate bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options.
FISCAL COMMENTS
According to the Senate Appropriations Committee, the Department of Managed Health Care estimates costs of approximately $64,000 in 2024-25 and $133,000 in 2025-26 and annually thereafter for state administration (Managed Care Fund). The California Department of Insurance estimates costs of $3,000 in 2023-24 for state administration (Insurance Fund)
VOTES:
ASM HEALTH: 14-1-0
YES: Wood, Waldron, Aguiar-Curry, Arambula, Boerner, Wendy Carrillo, Vince Fong, Maienschein, McCarty, Joe Patterson, Rodriguez, Santiago, Villapudua, Weber
NO: Flora
ASM APPROPRIATIONS: 14-1-1
YES: Holden, Megan Dahle, Bryan, Calderon, Wendy Carrillo, Mike Fong, Addis, Lowenthal, Papan, Pellerin, Robert Rivas, Sanchez, Weber, Wilson
NO: Dixon
ABS, ABST OR NV: Mathis
ASSEMBLY FLOOR: 68-1-11
YES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Chen, Connolly, Megan Dahle, Davies, Mike Fong, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Wallis, Ward, Weber, Wicks, Wood, Zbur, Rendon
NO: Dixon
ABS, ABST OR NV: Cervantes, Essayli, Flora, Vince Fong, Friedman, Gallagher, Mathis, Jim Patterson, Ta, Waldron, Wilson
SENATE FLOOR: 37-0-3
YES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Caballero, Cortese, Dahle, Dodd, Durazo, Eggman, Glazer, Gonzalez, Grove, Hurtado, Jones, Laird, Limón, McGuire, Menjivar, Min, Newman, Niello, Ochoa Bogh, Portantino, Roth, Rubio, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
ABS, ABST OR NV: Nguyen, Padilla, Seyarto
UPDATED
VERSION: July 13, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0001612
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 1288 |
THIRD READING
Bill No: AB 1288
Author: Rendon (D), et al.
Amended: 7/13/23 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 10-0, 7/12/23
AYES: Eggman, Glazer, Gonzalez, Hurtado, Limón, Menjivar, Roth, Rubio, Wahab, Wiener
NO VOTE RECORDED: Nguyen, Grove
SENATE APPROPRIATIONS COMMITTEE: 5-0, 8/14/23
AYES: Portantino, Ashby, Bradford, Wahab, Wiener
NO VOTE RECORDED: Jones, Seyarto
ASSEMBLY FLOOR: 68-1, 5/18/23 - See last page for vote
SUBJECT: Health care coverage: Medication-assisted treatment
SOURCE: Author
DIGEST:
- This bill prohibits a health plan or health insurer from requiring prior authorization or step therapy for a naloxone product or another opioid antagonist approved by the United States Food and Drug Administration, buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Services Plan Act of 1975; the California Department of Insurance (CDI) to regulate health and other insurers; Covered California as California’s health benefit exchange for individual and small business purchasers as authorized under the federal Patient Protection and Affordable Care Act (ACA); and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [Health & Safety Code (HSC) §1340, et seq., Insurance Code (INS) §106, et seq., Government Code (GOV) §100500 -100522, and Welfare & Institutions Code (WIC) §14000, et seq.]
- Requires health plans and insurers to cover basic health care services, and non-grandfathered individual and small group plans under the ACA to cover essential health benefits which includes prescription drug coverage. [HSC §1345, 1367.005 and INS §10112.27, §10112.281]
- Authorizes a health plan or insurer that provides coverage for prescription drugs to require step therapy if there is more than one drug that is clinically appropriate for the treatment of a medical condition. [HSC §1367.206 and INS §10123.201]
- Requires, if a health plan or health insurer that provides coverage for prescription drugs or a contracted physicians group fails to respond to a prior authorization, or step therapy exception request, as specified, within 72 hours for non-urgent requests, and within 24 hours if exigent circumstances exist, upon the receipt of a completed request form, the request to be deemed granted. [HSC §1367.241 and INS §10123.191]
- Requires every health plan contract and insurance policy that provides hospital, medical, or surgical coverage to provide coverage for medically necessary treatment of mental health and substance use disorders under the same terms and conditions applied to other medical conditions, as specified. [HSC §1374.72 and INS §10144.5]
This bill prohibits a health plan or health insurer from requiring prior authorization or step-therapy for a naloxone product or any other opioid antagonist approved by the FDA, buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder.
Comments
- Author’s statement. According to the author, this bill removes an unnecessary barrier to the use of medications for addiction treatment (MAT) in alleviating the effects substance use in California. This bill prohibits a health plan or insurer from requiring prior authorization for certain medications used for detoxification or the treatment of a substance use disorder. This will eliminate a cost-saving mechanism used by plans and insurers that delays access to these critical, often lifesaving medications and services.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Key findings include:
- Coverage impacts and enrollees covered.
- For Medi-Cal beneficiaries in DMHC-regulated managed care plans, the pharmacy benefit is separate and is administered by DHCS. Therefore, these beneficiaries have a pharmacy benefit that is not subject to DMHC regulation, or this bill.
- Among commercial/CalPERS enrollees, 1.2% do not have a pharmacy benefit and 3.2% have a pharmacy benefit that is not regulated by DMHC or CDI. Because this bill does not require coverage of the medications it addresses, baseline benefit coverage for enrollees without a pharmacy benefit or whose pharmacy benefit is not regulated by DMHC or CDI is compliant and would not change. Approximately 95.6% of commercial/CalPERS enrollees in plans and policies regulated by DMHC or CDI have a pharmacy benefit regulated by DMHC or CDI that would be subject to this bill. CHBRP estimates that 1% to 5% of these enrollees (the figure varies by medication) have a prior authorization requirement that this prohibits. Post-mandate, none of these enrollees would have a prior authorization requirement applicable to these medications when they are on formulary.
- Medical effectiveness.
- There is limited evidence that removal of prior authorization requirements for buprenorphine products is associated with increased use and higher treatment retention for opioid use disorder.
- There is insufficient evidence on the impact of prior authorization on methadone use for opioid use disorder.
- There is insufficient evidence on the impact of prior authorization on long-acting injectable naltrexone use for either opioid use disorder or alcohol use disorder.
- For treatment of opioid use disorder, there is clear and convincing evidence that buprenorphine products and methadone are more effective with regard to treatment retention, reduction in use of illicit opioids, relapse, and improved health outcomes, compared to a placebo or no treatment.
- There is a preponderance of evidence that long-acting injectable naltrexone is effective with regard to treatment retention and abstinence, but not for overdose prevention, compared to a placebo or oral naltrexone.
- For treatment of alcohol use disorder, there is a preponderance of evidence that long-acting injectable naltrexone is more effective with regard to reducing return to drinking compared to a placebo or oral naltrexone.
- Utilization. No measurable change in utilization or expenditures at the state level is expected because benefit coverage would change for very few commercial/CalPERS enrollees (1% to 5% of depending on the medication) and few in that group would both have one of the disorders and be a likely user of one of the medications. However, it is possible that a few enrollees might increase utilization of the medications addressed by this bill, postmandate.
- Impact on expenditures. No measurable change in utilization or expenditures at the state level is expected because benefit coverage would change for very few commercial/CalPERS enrollees (1% to 5% of depending on the medication) and few in that group would both have one of the disorders and be a likely user of one of the medications. However, it is possible that a few enrollees might increase utilization of the medications addressed by this bill, postmandate.
- Coverage impacts and enrollees covered.
- Medi-Cal coverage. According to DHCS, Behavioral Health Information Notice 23-001, Medi-Cal providers are required to either offer MAT, directly, or have effective referral mechanisms in place to the most clinically appropriate MAT services (defined as facilitating access to MAT off-site for beneficiaries while they are receiving outpatient treatment services if not provided on-site. Providing a beneficiary the contact information for a treatment program is insufficient). Outpatient treatment services include the following service components:
- Assessment
- Care Coordination
- Counseling (individual and group)
- Family Therapy
- Medication Services
- MAT for Opioid Use Disorder
- MAT for Alcohol Use Disorder and other non-opioid Substance Use Disorder
- Patient Education
- Recovery Services
- SUD Crisis Intervention Services
Additionally, MAT may be provided in clinical or non-clinical settings and can be delivered as a standalone service or as a service delivered as part of a level of care listed in this “Covered Drug Medi-Cal-Organized Deliver System Services” section. MAT may be provided with the following service components:
- Assessment
- Care Coordination
- Counseling (individual and group)
- Family Therapy
- Medication Services
- Patient Education
- Recovery Services
- Substance Use Disorder Crisis Intervention Services
- Withdrawal Management Services
MAT for Opioid Use Disorder includes all medications approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and all biological products licensed under section 351 of the Public Health Service Act (42 U.S.C. 262) to treat Opioid Use Disorder.
- Medicare coverage. Medicare covers U.S. FDA-approved opioid agonist and antagonist MAT medications and dispensing and administering MAT medications, if applicable, through Opioid Treatment Programs.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee:
- DMHC estimates costs of approximately $64,000 in 2024-25 and $133,000 in 2025-26 and annually thereafter for state administration (Managed Care Fund).
- CDI estimates costs of $3,000 in 2023-24 for state administration (Insurance Fund).
SUPPORT: (Verified 8/15/23)
Alameda-Contra Costa Medical Association
Alkermes, Inc.
California Academy of Family Physicians
California Association of Family Physicians
California Health+Advocates
California Life Sciences
California Society of Addiction Medicine
California State Association of Psychiatrists
Connection Coalition
County Behavioral Health Directors Association of California
National Health Law Program
Steinberg Institute
OPPOSITION: (Verified 8/15/23)
America’s Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: The California Association of Family Physicians writes that this bill takes strides to alleviate barriers to accessing medication to treat substance abuse.
The National Health Law Program writes that, given how beneficial MAT is for patients with opioid use disorder, California must ensure that patients can access the service without delay. Prohibiting plans from imposing prior authorization, as this bill seeks, is an important and essential step in that direction.
The Steinberg Institute writes that skyrocketing overdose rates represent a public health emergency, demanding new strategies of response, including the removal of unnecessary barriers to effective treatment, and this bill is an important first step that will reduce overdose rates and save lives.
California Health+ Advocates writes that the recently passed federal MAT Act removed barriers for prescribers to initiate and continue MAT for patients with substance use disorders. MAT works by treating craving and withdrawal symptoms. Those prescribed medications are effective in decreasing overdose, decreasing emergency department and hospital utilization, decreasing relapse, and preventing death. Studies have documented a 60% reduction in overdose deaths for those using MAT. However, health insurers continue to impose prior authorization requirements that can delay access to necessary treatment. Subsequently MAT is grossly underutilized, in 2019, only 7.5% of patients with opioid use disorder received buprenorphine and only 13% received any medication treatment. Commonly cited barriers include insurance challenges such as prior authorization.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans, the Association of California Life & Health Insurance Companies, and America’s Health Insurance Plans write in opposition to this along with 20 other health insurance mandate bills. These bills include mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost sharing and limit utilization management, which have similar cost impacts as coverage mandates. Taken together, these bills will increase premiums by at least $742,533,000 in 2024 alone, with projected additional increases in out years. Ultimately, these bills will harm affordability and access for small businesses and individual market consumers. Moreover, they will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. State mandates increase costs of coverage – especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Benefit mandates that do not promote evidence-based medicine can lead to lower quality care, over- or misutilization of services, and higher costs for treatments that may be ineffective, less safe, or higher cost than other, new or trusted services. California is rightly focused on achieving both universal coverage and cost containment at a time when the national conversation has shifted toward lower costs through less comprehensive options.
ASSEMBLY FLOOR: 68-1, 5/18/23
AYES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Chen, Connolly, Megan Dahle, Davies, Mike Fong, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Wallis, Ward, Weber, Wicks, Wood, Zbur, Rendon
NOES: Dixon
NO VOTE RECORDED: Cervantes, Essayli, Flora, Vince Fong, Friedman, Gallagher, Mathis, Jim Patterson, Ta, Waldron, Wilson
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
8/16/23 14:22:06
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anthony Portantino, Chair
2023 - 2024 Regular Session
AB 1288 (Rendon) - Health care coverage: Medication-assisted treatment
Version: July 13, 2023 | Policy Vote: HEALTH 10 - 0 |
Urgency: No | Mandate: Yes |
Hearing Date: August 14, 2023 | Consultant: Agnes Lee |
Bill Summary:
AB 1288 would prohibit a health plan or insurer from subjecting certain products used to treat substance use disorders, to prior authorization or step therapy.
Fiscal Impact:
- The Department of Managed Health Care (DMHC) estimates costs of approximately $64,000 in 2024-25 and $133,000 in 2025-26 and annually thereafter for state administration (Managed Care Fund).
- The California Department of Insurance (CDI) estimates costs of $3,000 in 2023-24 for state administration (Insurance Fund).
Background:
Existing law establishes the DMHC to regulate health plans under the Knox-Keene Act and the CDI to regulate health insurance. Current law requires every health plan and disability insurance policy that provides hospital, medical, or surgical coverage to provide coverage for medically necessary treatment of mental health and substance use disorders, under the same terms and conditions applied to other medical conditions, as specified. Current law defines “medically necessary treatment of mental health or substance use disorder” to include that the service or product is in accordance with generally accepted standards of mental health or substance use disorder care, clinically appropriate in terms of type, frequency, extent, site, and duration.
Prior authorization is when the health plan/insurer or pharmacy benefit manager must authorize a particular prescription before it can be filled. Step therapy is a type of prior authorization for drugs that begins medication for a medical condition with the most preferred drug therapy and progresses to other therapies only if necessary, promoting better clinical decisions. Prior authorization also may be used in conjunction with a step therapy system, so that a patient might be required to try a less expensive drug before receiving authorization to receive the drug originally requested. State law permits, if there is more than one drug that is clinically appropriate for the treatment of a medical condition, a health plan or insurer that provides coverage for prescription drugs to require step therapy.
If a health plan or insurer that provides coverage for prescription drugs fails to respond to a prior authorization or step therapy exception request within 72 hours for non-urgent requests, and within 24 hours if exigent circumstances exist, upon the receipt of a completed form, the request is deemed granted.
Proposed Law:
AB 1288 would prohibit a health plan or insurer from subjecting any of the following to prior authorization or step therapy:
- A naloxone product or another opioid antagonist approved by the United States Food and Drug Administration.
- A buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder.
Staff Comments:
The California Health Benefits Review Program (CHBRP) analysis of AB 1288, as introduced, estimates that while it is possible that a few health plan/insurer enrollees might increase utilization of these medications, there would be no measurable change in utilization or expenditures. Because the prescription drug benefit for Medi-Cal beneficiaries is not subject to DMHC regulation, the bill would not impact the Medi-Cal program.
-- END --
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anthony Portantino, Chair
2023 - 2024 Regular Session
AB 1288 (Rendon) - Health care coverage: Medication-assisted treatment
Version: July 13, 2023 | Policy Vote: HEALTH 10 - 0 |
Urgency: No | Mandate: Yes |
Hearing Date: August 14, 2023 | Consultant: Agnes Lee |
Bill Summary:
AB 1288 would prohibit a health plan or insurer from subjecting certain products used to treat substance use disorders, to prior authorization or step therapy.
Fiscal Impact:
- The Department of Managed Health Care (DMHC) estimates costs of approximately $64,000 in 2024-25 and $133,000 in 2025-26 and annually thereafter for state administration (Managed Care Fund).
- The California Department of Insurance (CDI) estimates costs of $3,000 in 2023-24 for state administration (Insurance Fund).
Background:
Existing law establishes the DMHC to regulate health plans under the Knox-Keene Act and the CDI to regulate health insurance. Current law requires every health plan and disability insurance policy that provides hospital, medical, or surgical coverage to provide coverage for medically necessary treatment of mental health and substance use disorders, under the same terms and conditions applied to other medical conditions, as specified. Current law defines “medically necessary treatment of mental health or substance use disorder” to include that the service or product is in accordance with generally accepted standards of mental health or substance use disorder care, clinically appropriate in terms of type, frequency, extent, site, and duration.
Prior authorization is when the health plan/insurer or pharmacy benefit manager must authorize a particular prescription before it can be filled. Step therapy is a type of prior authorization for drugs that begins medication for a medical condition with the most preferred drug therapy and progresses to other therapies only if necessary, promoting better clinical decisions. Prior authorization also may be used in conjunction with a step therapy system, so that a patient might be required to try a less expensive drug before receiving authorization to receive the drug originally requested. State law permits, if there is more than one drug that is clinically appropriate for the treatment of a medical condition, a health plan or insurer that provides coverage for prescription drugs to require step therapy.
If a health plan or insurer that provides coverage for prescription drugs fails to respond to a prior authorization or step therapy exception request within 72 hours for non-urgent requests, and within 24 hours if exigent circumstances exist, upon the receipt of a completed form, the request is deemed granted.
Proposed Law:
AB 1288 would prohibit a health plan or insurer from subjecting any of the following to prior authorization or step therapy:
- A naloxone product or another opioid antagonist approved by the United States Food and Drug Administration.
- A buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder.
Staff Comments:
The California Health Benefits Review Program (CHBRP) analysis of AB 1288, as introduced, estimates that while it is possible that a few health plan/insurer enrollees might increase utilization of these medications, there would be no measurable change in utilization or expenditures. Because the prescription drug benefit for Medi-Cal beneficiaries is not subject to DMHC regulation, the bill would not impact the Medi-Cal program.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Susan Talamantes Eggman, Chair
BILL NO: AB 1288
AUTHOR: | Rendon | ||
VERSION: | July 5, 2023 | ||
HEARING DATE: | July 12, 2023 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Health care coverage: Medication-assisted treatment
SUMMARY:
- Prohibits a health plan or health insurer from requiring prior authorization or step therapy for a naloxone product, buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder.
Existing law:
- Establishes: the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Services Plan Act of 1975; the California Department of Insurance (CDI) to regulate health and other insurers; Covered California as California’s health benefit exchange for individual and small business purchasers as authorized under the federal Patient Protection and Affordable Care Act (ACA); and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., GOV §100500 -100522, and WIC §14000, et seq.]
- Requires health plans and insurers to cover basic health care services, and nongrandfathered individual and small group plans under the ACA to cover essential health benefits which includes prescription drug coverage. [HSC §1345, 1367.005 and INS §10112.27, §10112.281]
- Authorizes a health plan or insurer that provides coverage for prescription drugs to require step therapy if there is more than one drug that is clinically appropriate for the treatment of a medical condition. [HSC §1367.206 and INS §10123.201]
- Requires, if a health plan or health insurer that provides coverage for prescription drugs or a contracted physicians group fails to respond to a prior authorization, or step therapy exception request, as specified, within 72 hours for nonurgent requests, and within 24 hours if exigent circumstances exist, upon the receipt of a completed request form, the request to be deemed granted. [HSC §1367.241 and INS §10123.191]
- Requires every health plan contract and insurance policy that provides hospital, medical, or surgical coverage to provide coverage for medically necessary treatment of mental health and substance use disorders under the same terms and conditions applied to other medical conditions, as specified. [HSC §1374.72 and INS §10144.5]
- Requires the criteria or guidelines used by health plans and insurers, or any entities with which plans or insurers contract for utilization review or utilization management functions, to determine whether to authorize, modify, or deny health care services to:
- Be developed with involvement from actively practicing health care providers;
- Be consistent with sound clinical principles and processes;
- Be evaluated, and updated if necessary, at least annually;
- If used as the basis of a decision to modify, delay, or deny services in a specified case under review, be disclosed to the provider and the enrollee or insured in that specified case; and,
- Be available to the public upon request. [HSC §1363.5 and INS §10123.135]
- Prohibits any individual, other than a licensed physician or a licensed health care professional who is competent to evaluate the specific clinical issues involved in the health care services requested by the provider, from denying or modifying requests for authorization of health care services for an enrollee or insured for reasons of medical necessity. Requires the decision to be communicated to the provider within 24 hours of the decision, and the enrollee or insured (in writing) within two business days of the decision. In the case of concurrent review, prohibits discontinuance of care until the treating provider has been notified and has agreed to a care plan that is appropriate for the medical needs of the patient. [HSC §1367.01 and INS §10123.135]
- Requires under federal law a group health plan and a health insurance issuer offering group or individual health insurance coverage to implement an effective appeals process for appeals of coverage determinations and claims, including an internal claims appeal process with notices in a culturally and linguistically appropriate manner, of available internal and external appeals process. Establishes processes for internal and external reviews. [42 U.S.C. §300gg-19]
This bill: Prohibits a health plan or health insurer from requiring prior authorization or step-therapy for a naloxone product, buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder.
FISCAL EFFECT:
According to the Assembly Appropriations Committee, CDI estimates costs of $3,000 in fiscal year (FY) 2023-24 (Insurance Fund). DMHC estimates the total cost of this bill to be approximately $64,000 in FY 2024-25 and $133,000 in FY 2025-26 and annually thereafter (Managed Care Fund). DMHC's Office of Plan Monitoring anticipates costs for additional workload to develop a methodology and assess compliance during health plan surveys, and for clinical and statistical consultant funding.
PRIOR VOTES:
Assembly Floor: | 68 - 1 |
Assembly Appropriations Committee: | 14 - 1 |
Assembly Health Committee: | 14 - 1 |
COMMENTS:
- Author’s statement. According to the author, this bill removes an unnecessary barrier to the use of medications for addiction treatment (MAT) in alleviating the effects substance use in California. This bill will prohibit a health plan or insurer from requiring prior authorization for certain medications used for detoxification or the treatment of a substance use disorder. This will eliminate a cost-saving mechanism used by plans and insurers that delays access to these critical, often lifesaving medications and services.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Key findings include:
- Coverage impacts and enrollees covered.
- Medi-Cal. For Medi-Cal beneficiaries in DMHC-regulated managed care plans, the pharmacy benefit is separate and is administered by DHCS. Therefore, these beneficiaries have a pharmacy benefit that is not subject to DMHC regulation, or this bill.
- CalPERS. Among commercial/CalPERS enrollees, 1.2% do not have a pharmacy benefit and 3.2% have a pharmacy benefit that is not regulated by DMHC or CDI. Because this bill does not require coverage of the medications it addresses, baseline benefit coverage for enrollees without a pharmacy benefit or whose pharmacy benefit is not regulated by DMHC or CDI is compliant and would not change. Approximately 95.6% of commercial/CalPERS enrollees in plans and policies regulated by DMHC or CDI have a pharmacy benefit regulated by DMHC or CDI that would be subject to this bill. CHBRP estimates that 1% to 5% of these enrollees (the figure varies by medication) have a prior authorization requirement that would be prohibited by this bill. Postmandate, none of these enrollees would have a prior authorization requirement applicable to these medications when they are on formulary.
- Medical effectiveness.
- There is limited evidence that removal of prior authorization requirements for buprenorphine products is associated with increased use and higher treatment retention for opioid use disorder.
- There is insufficient evidence on the impact of prior authorization on methadone use for opioid use disorder.
- There is insufficient evidence on the impact of prior authorization on long-acting injectable naltrexone use for either opioid use disorder or alcohol use disorder.
- For treatment of opioid use disorder, there is clear and convincing evidence that buprenorphine products and methadone are more effective with regard to treatment
retention, reduction in use of illicit opioids, relapse, and improved health outcomes, compared to a placebo or no treatment. - There is a preponderance of evidence that long-acting injectable naltrexone is effective with regard to treatment retention and abstinence, but not for
overdose prevention, compared to a placebo or oral naltrexone. - For treatment of alcohol use disorder, there is a preponderance of evidence that long-acting injectable naltrexone is more effective with regard to reducing return to drinking compared to a placebo or oral naltrexone.
- Utilization. No measurable change in utilization or expenditures at the state level is expected because benefit coverage would change for very few commercial/CalPERS enrollees (1% to 5% of depending on the medication) and few in that group would both have one of the disorders and be a likely user of one of the medications. However, it is possible that a few enrollees might increase utilization of the medications addressed by this bill, postmandate.
- Impact on expenditures. No measurable change in utilization or expenditures at the state level is expected because benefit coverage would change for very few commercial/CalPERS enrollees (1% to 5% of depending on the medication) and few in that group would both have one of the disorders and be a likely user of one of the medications. However, it is possible that a few enrollees might increase utilization of the medications addressed by this bill, postmandate.
- Coverage impacts and enrollees covered.
- Medi-Cal coverage. According to DHCS, Behavioral Health Information Notice 23-001, Medi-Cal providers are required to either offer MAT, directly, or have effective referral mechanisms in place to the most clinically appropriate MAT services (defined as facilitating access to MAT off-site for beneficiaries while they are receiving outpatient treatment services if not provided on-site. Providing a beneficiary the contact information for a treatment program is insufficient). Outpatient treatment services include the following service components:
- Assessment
- Care Coordination
- Counseling (individual and group)
- Family Therapy
- Medication Services
- MAT for Opioid Use Disorder
- MAT for Alcohol Use Disorder and other non-opioid Substance Use Disorder
- Patient Education
- Recovery Services
- SUD Crisis Intervention Services
Additionally, MAT may be provided in clinical or non-clinical settings and can be delivered as a standalone service or as a service delivered as part of a level of care listed in this “Covered Drug Medi-Cal-Organized Deliver System Services” section. MAT may be provided with the following service components:
- Assessment
- Care Coordination
- Counseling (individual and group)
- Family Therapy
- Medication Services
- Patient Education
- Recovery Services
- Substance Use Disorder Crisis Intervention Services
- Withdrawal Management Services
MAT for Opioid Use Disorder includes all medications approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and all biological products licensed under section 351 of the Public Health Service Act (42 U.S.C. 262) to treat Opioid Use Disorder.
- Medicare coverage. Medicare covers through Opioid Treatment Programs U.S. FDA-approved opioid agonist and antagonist MAT medications and dispensing and administering MAT medications, if applicable.
- Related legislation. AB 1060 (Ortega) requires coverage of prescription or nonprescription naloxone hydrochloride under a health plan contract, health insurance policy, and the Medi-Cal program, if that medication is approved, for prescription or nonprescription use, respectively, by the United States Food and Drug Administration for treatment of an opioid overdose. Prohibits a health plan contract or health insurance policy from imposing any cost-sharing requirements. AB 1060 is pending in the Senate Appropriations Committee Suspense File.
- Prior legislation. SB 834 (Beall of 2020) would have required health plan contracts and health insurance policies that provide outpatient prescription drug benefits to cover all medically necessary prescription drugs approved by the United States FDA for treating substance use disorders that are appropriate for the specific needs of an enrollee or insured. SB 834 would have required those drugs to be placed on the lowest cost-sharing tier of the plan or insurer’s prescription drug formulary, unless specified criteria are met. SB 834 would have, among other prohibitions, prohibited prior authorization or step therapy requirements on a prescription drug approved by the FDA for treating substance use diosrders, unless specified criteria are met. SB 834 was not heard in the Senate Health Committee.
AB 2384 (Arambula of 2018) would have required a health plan (excluding Medi-Cal managed care plans), or a health insurer that provides prescription drug benefits, to cover, at a minimum, at least one version of each of MAT, relapse prevention, or overdose reversal prescriptions drugs approved by the FDA, for opioids use disorder regardless of whether a drug is self-administered or administered by a health care provider, as specified. SB 2384 was vetoed by the Governor, who stated:
This bill requires health plans to cover at least one version of each drug used in medication-assisted treatment for opioid disorders and restricts health plans' ability to manage the utilization of these drugs. While the drugs specified in this bill are useful to treat opioid addiction, I'm not willing to eliminate requirements that may be in the best interest of patients.
- Support. The California Association of Family Physicians writes this bill takes strides to alleviate barriers to accessing medication to treat substance abuse. The National Health Law Program writes given how beneficial MAT is for patients with opioid use disorder, California must ensure that patients can access the service without delay. Prohibiting plans from imposing prior authorization, as this bill seeks, is an important and essential step in that direction. The Steinberg Institute writes skyrocketing overdose rates represent a public health emergency, demanding new strategies of response, including the removal of unnecessary barriers to effective treatment, and this bill is an important first step that will reduce overdose rates and save lives. California Health+ Advocates writes that the recently passed federal MAT Act removed barriers for prescribers to initiate and continue MAT for patients with substance use disorders. MAT works by treating craving and withdrawal symptoms. Those prescribed medications are effective in decreasing overdose, decreasing emergency department and hospital utilization, decreasing relapse, and preventing death. Studies have documented a 60% reduction in overdose deaths for those using MAT. However, health insurers continue to impose prior authorization requirements that can delay access to necessary treatment. Subsequently MAT is grossly underutilized, in 2019, only 7.5% of patients with opioid use disorder received buprenorphine and only 13% received any medication treatment. Commonly cited barriers include insurance challenges such as prior authorization.
- Opposition. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write in opposition to this along with 20 other health insurance mandate bills. These bills include mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost sharing and limit utilization management, which have similar cost impacts as coverage mandates. Taken together, these bills will increase premiums by at least $742,533,000 in 2024 alone, with projected additional increases in out years. Ultimately, these bills will harm affordability and access for small businesses and individual market consumers. Moreover, they will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. State mandates increase costs of coverage – especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Benefit mandates that do not promote evidence-based medicine can lead to lower quality care, over- or misutilization of services, and higher costs for treatments that may be ineffective, less safe, or higher cost than other, new or trusted services. California is rightly focused on achieving both universal coverage and cost containment at a time when the national conversation has shifted toward lower costs through less comprehensive options.
- Amendments. With the recent addition of naloxone to the bill, the committee may wish to amend this bill to account for “other FDA approved opioid antagonists” as well.
SUPPORT AND OPPOSITION:
Support: Alameda-Contra Costa Medical Association
Alkermes, Inc.
California Academy of Family Physicians
California Health+Advocates
California Life Sciences
California Society of Addiction Medicine
California State Association of Psychiatrists
County Behavioral Health Directors Association of California
National Health Law Program
Steinberg Institutes
Oppose: America’s Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1288
Author:(Reyes)
As Introduced Ver:February 16, 2023
Majority vote
SUMMARY
Prohibits a health plan and a health insurer from requiring prior authorization for a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder (SUD) that is prescribed according to generally accepted national professional guidelines.
Major Provisions
COMMENTS
This bill prohibits health plans and insurance policies from requiring prior authorization for buprenorphine products, methadone, or long-acting injectable naltrexone for detoxification (medically supervised withdrawal) or maintenance treatment of a SUD that is prescribed according to generally accepted national professional guidelines for the treatment of an SUD. According to the California Health Benefits Review Program (CHBRP), the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defines opioid use disorder (OUD) as "a problematic pattern of opioid use leading to clinically significant impairment or distress" and persons must meet at least two of the defined criteria within a 12-month period to receive a diagnosis. OUD applies to the class of medications or drugs that includes illegal drugs such as heroin, synthetic opioids such as fentanyl, and prescription pain medications such as oxycodone, hydrocodone, codeine, and morphine that are misused for indications other than prescribed. Prescription opioids are used to treat moderate to severe pain, and persons who take prescription opioids can develop opioid use disorder.
The DSM-5 characterizes alcohol use disorder as a pattern of alcohol use (e.g., wine, beer, and spirits) that results in significant impairment or distress. People meeting at least two of 11 specified criteria within a 12-month period are diagnosed with mild, moderate, or severe alcohol use disorder depending on the number of criteria met.
OUD prevalence in California was 1.58% among people aged 12 years and older in 2021. In the United States, among those reporting a prescription opioid use disorder, 35.2% also report alcohol use disorder. Alcohol use disorder prevalence in California was 11% among people aged 12 or older in 2021. In the United States, among those reporting alcohol use disorder, 3.9% report a related prescription opioid use disorder. In 2017, the U.S. Surgeon General declared the opioid crisis a U.S. public health emergency due to the escalating rates of opioid overdose, and related mortality and other harms. In addition to a greater risk of mortality and premature mortality, people with opioid use disorder are at a higher risk for developing cardiac dysrhythmias; respiratory depression; impairment in daily function; and contraction of infections including HIV, hepatitis (A, B, and C), tuberculosis, and endocarditis, which lead to increased use of health care services to treat those conditions.
The Substance Abuse and Mental Health Services Administration (SAMHSA) describes maintenance treatment as "providing medications to achieve and sustain clinical remission of signs and symptoms of OUD and support the individual process of recovery without a specific endpoint." Some persons with OUD may require long-term medication treatment to ensure sustained recovery. There is evidence that relapse of OUD occurs less often for patients on medications (buprenorphine-naloxone and long-acting injectable naltrexone) for treatment (16%) compared to patients with no medication for treatment (40%). Some persons with alcohol use disorder experience a chronic condition with recurring treatment, abstinence, and relapse. Data from a nationally representative sample from 2012 to 2013 found that one third of adults with alcohol use disorder prior to the past year still had persistent alcohol use disorder, over half had remission from alcohol use disorder as classified by the DSM-5, and of the respondents that met criteria for remission, one third were indicative of recovery.
- Opioid Related Overdose Deaths in California. The Department of Public Health reports on its Opioid Overdose Death Dashboard that in 2021, there were 7,175 opioid related deaths in California. Of those over 83% involved fentanyl, a potent synthetic opioid drug that is approximately 50 times stronger than heroin and 100 times stronger than morphine. The number of deaths each year involving fentanyl increased dramatically between 2012 and 2021. During this time period fentanyl related overdose deaths increased by more than 7,250% -- from 82 deaths to 5,961 deaths in 2021.
In 2019, almost one third of white persons with opioid use disorder received medications for treatment compared to 20% of Black or other non-Latino multiracial groups and 15% of Latino persons. Prescribing practices changed significantly for medications prescribed for OUD (buprenorphine and long-acting injectable naltrexone) after the beginning of the COVID-19 pandemic, with 30.5% decrease for buprenorphine and 10.5% decrease of long-acting injectable naltrexone across all races/ethnicities. However, Black, Latino, and Asian persons experienced greater decreases in buprenorphine prescription fills compared to white persons. Racial disparities in overdoses have emerged with greater increases among Black and Latino persons. In California, the opioid-related overdose death rate was highest among American Indian/Alaskan Native and Black persons compared to white persons and healthcare utilization for opioid-related overdoses in the emergency department and hospitalization was highest among Black persons during 2021.
- Medication-assisted treatment (MAT). Treatments for SUD include prescription medication (medications for OUD or medications for alcohol use disorder), also called MAT, as well as counseling, residential facilities, and mutual help groups (e.g., Alcoholics Anonymous, Narcotics Anonymous). This bill lists three U.S. Food and Drug Administration (FDA)-approved MAT options for OUD and alcohol use disorder: buprenorphine products, methadone, or long-acting injectable naltrexone. Methadone as a treatment for OUD is only available from opioid treatment programs (OTPs). Rules governing OTPs exist at both the federal and state levels: The federal government establishes baseline requirements for OTPs, and states layer additional requirements on top of them. The American Society of Addiction Medicine (ASAM) provides the National Practice Guidelines for the Use of Medications in the Treatment of Addiction Involving Opioid Use and SAMHSA provides the Treatment Improvement Protocol that reviews the clinical standards of care for patients with OUD including buprenorphine, methadone, and long-acting injectable naltrexone. In 2020, the ASAM updated requirements to include that all FDA approved medication prescribed for the treatment of OUD should be available to all persons seeking treatment.
- CHBRP analysis. CHBRP states the following in its analysis of this bill:
- Impact on utilization and expenditures. According to CHBRP, no measurable change in utilization or expenditures at the state level is expected because benefit coverage would change for very few commercial/CalPERS enrollees (1% to 5% of depending on the medication) and few in that group would both have one of the disorders and be a likely user of one of the medications. However, it is possible that a few enrollees might increase utilization of the medications addressed by this bill, postmandate.
- Medical effectiveness. There is limited evidence that removal of prior authorization requirements for buprenorphine products is associated with increased use and higher treatment retention for OUD. There is insufficient evidence on the impact of prior authorization on methadone use for OUD. There is insufficient evidence on the impact of prior authorization on long-acting injectable naltrexone use for either OUD or alcohol use disorder. For treatment of OUD, there is clear and convincing evidence that buprenorphine products and methadone are more effective with regard to treatment retention, reduction in use of illicit opioids, relapse, and improved health outcomes, compared to a placebo or no treatment. There is a preponderance of evidence that long-acting injectable naltrexone is effective with regard to treatment retention and abstinence, but not for overdose prevention, compared to a placebo or oral naltrexone. For treatment of alcohol use disorder, there is a preponderance of evidence that long-acting injectable naltrexone is more effective with regard to reducing return to drinking compared to a placebo or oral naltrexone.
- Public Health. CHBRP projects no measurable public health impact at the population level because this bill is not expected to create measurable changes in benefit coverage for or utilization at the state level. However, it is possible that this bill could yield some person-level health improvements if some enrollees increase utilization of the medications this bill addresses.
- Long-Term Impacts. Since the change in benefit coverage is so limited, no state-level long-term impacts of this bill on health outcomes, including premature death associated with OUD and alcohol use disorder, can be projected. However, if some enrollees increase utilization of the medications addressed by this bill, it is possible that there could be some reduction in premature deaths at the person level.
According to the Author
There is an urgent need to expand access to rapid initiation of medications to treat addiction. This bill expands on the recent work of the federal government to mainstream addiction treatment by eliminating unnecessary barriers to treatment. As a policy, commercially insured Californians are the only group where prior authorization delays are still allowed. The author concludes that by removing this last barrier this bill will expand low barrier treatment options for at risk patients, prevent overdose and save lives.
Arguments in Support
National Health Law Program (NHLP) writes that for the past several years, California has made concerted efforts to increase access to MAT. One of these efforts has been ensuring that health plans across the state provide comprehensive coverage for all FDA-approved medications to treat OUD. As a result, both Medi-Cal and private health plans now offer coverage for methadone, buprenorphine, and naltrexone, as well as for services associated with effective use of these medications, such as ordering, prescribing, administering, and counseling. Despite these gains, however, many private plans continue to sidestep their responsibility to cover MAT by imposing utilization controls that only serve to reduce the costs to the plan, while establishing barriers to care and putting the lives of people with OUD at risk. The most commonly used of these utilization control techniques is prior authorization, an onerous requirement that delays access to lifesaving services without any significant benefit to the patient. Imposing prior authorization on MAT may also represent a violation of federal behavioral health parity requirements if it is applied disproportionately to MAT and other SUD treatment over physical health services. Given how beneficial MAT is for patients with OUD, California must ensure that patients can access the service without delay. NHLP states that prohibiting plans from imposing prior authorization is an important and essential step in that direction.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. The opposition states mandate bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options.
FISCAL COMMENTS
According to the Assembly Appropriations Committee, the California Department of Insurance estimates costs of $3,000 in fiscal year (FY) 2023-24 (Insurance Fund). The Department of Managed Health Care (DMHC) estimates the total cost of this bill to be approximately $64,000 in FY 2024-25 and $133,000 in FY 2025-26 and annually thereafter (Managed Care Fund). DMHC's Office of Plan Monitoring anticipates costs for additional workload to develop a methodology and assess compliance during health plan surveys, and for clinical and statistical consultant funding.
VOTES
ASM HEALTH: 14-1-0
YES: Wood, Waldron, Aguiar-Curry, Arambula, Boerner, Wendy Carrillo, Vince Fong, Maienschein, McCarty, Joe Patterson, Rodriguez, Santiago, Villapudua, Weber
NO: Flora
ASM APPROPRIATIONS: 14-1-1
YES: Holden, Megan Dahle, Bryan, Calderon, Wendy Carrillo, Mike Fong, Addis, Lowenthal, Papan, Pellerin, Robert Rivas, Sanchez, Weber, Wilson
NO: Dixon
ABS, ABST OR NV: Mathis
UPDATED
VERSION: February 16, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0000359
Date of Hearing: May 10, 2023
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Chris Holden, Chair
ABPCA Bill Id:AB 1288
Author:(Reyes) – As Introduced Ver:February 16, 2023
Policy Committee: | Health | Vote: | 14 - 1 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill prohibits a health plan and a health insurer from requiring prior authorization for a buprenorphine product, methadone, or long-acting injectable naltrexone that is prescribed according to generally accepted professional guidelines for detoxification or maintenance treatment of a substance use disorder (SUD).
FISCAL EFFECT:
The California Department of Insurance (CDI) estimates costs of $3,000 in fiscal year (FY) 2023-24 (Insurance Fund).
The Department of Managed Health Care (DMHC) estimates the total cost of this bill to be approximately $64,000 in FY 2024-25 and $133,000 in FY 2025-26 and annually thereafter (Managed Care Fund). DMHC’s Office of Plan Monitoring anticipates costs for additional workload to develop a methodology and assess compliance during health plan surveys, and for clinical and statistical consultant funding.
COMMENTS:
- Purpose. According to the author:
There is an urgent need to expand access to rapid initiation of medications to treat addiction. This bill expands on the recent work of the federal government to mainstream addiction treatment by eliminating unnecessary barriers to treatment. As a policy, commercially insured Californians are the only group where prior authorization delays are still allowed. Removing this last barrier will expand low barrier treatment options for at risk patients, prevent overdose and save lives.
According to a 2017 report by the California Healthcare Foundation, one of the barriers to prescribers incorporating addiction treatment into their practice is the administrative burden of insurance authorizations.
- Medication-assisted Treatment (MAT). Treatments for SUD include prescription medication (for opioid use disorder (OUD) or alcohol use disorder), also called MAT, as well as counseling, residential facilities, and mutual help groups (such as Alcoholics Anonymous). This bill lists three U.S. Food and Drug Administration (FDA)-approved MAT options for OUD and alcohol use disorder: buprenorphine products, methadone, or long-acting injectable naltrexone. Methadone as a treatment for OUD is only available from opioid treatment programs. The American Society of Addiction Medicine (ASAM) provides the National Practice Guidelines for the Use of Medications in the Treatment of Addiction Involving Opioid Use. In 2020, the ASAM guidelines state that all FDA-approved medication prescribed for the treatment of OUD should be available to all persons seeking treatment.
At least 18 states and the District of Columbia limit prior authorization on medications used to treat SUDs. The federal Consolidated Appropriations Act of 2023 removed the federal requirement that providers submit a Notice of Intent (waiver) to prescribe buprenorphine for OUD treatment and removed limits on the number of patients a practitioner may treat. This allows a qualified provider to prescribe buprenorphine for OUD treatment as allowed by scope of practice in each state. - California Health Benefits Review Program (CHBRP) Report. According to CHBRP, approximately 1.6% of Californians over the age of 12 years have OUD, and 11% have alcohol use disorder. There are disparities in the prevalence of the disorders, treatment, and outcomes by race/ethnicity, sex or gender, and sexual orientation.
CHBRP states 95.6% of commercial or CalPERS enrollees in plans and policies regulated by DMHC or CDI have a DMHC- or CDI-regulated pharmacy benefit that are subject to this bill, and 1% to 5% of these enrollees (the figure varies by medication) have a prior authorization requirement that the bill prohibits. CHBRP expects no measurable change in utilization or expenditures at the state level as a result of this bill.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 25, 2023
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 1288
Author:(Reyes) – As Introduced Ver:February 16, 2023
SUBJECT: Health care coverage: Medication-assisted treatment.
SUMMARY: Prohibits a health plan and a health insurer from requiring prior authorization for a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder (SUD) that is prescribed according to generally accepted national professional guidelines.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans and the California Department of Insurance (CDI) to regulate health insurance. [Health and Safety Code (HSC) §1340, et seq., Insurance Code (INS) §106, et seq.]
- Requires the criteria or guidelines used by health plans and insurers, or any entities with which plans or insurers contract for utilization review or utilization management functions, to determine whether to authorize, modify, or deny health care services to:
- Be developed with involvement from actively practicing health care providers;
- Be consistent with sound clinical principles and processes;
- Be evaluated, and updated if necessary, at least annually;
- If used as the basis of a decision to modify, delay, or deny services in a specified case under review, be disclosed to the provider and the enrollee or insured in that specified case; and,
- Be available to the public upon request. [HSC §1363.5 and INS §10123.135]
- Requires health plans and insurers and any contracted entity that performs utilization review or utilization management functions, retrospectively, or concurrently, based in whole or in part on medical necessity requests by providers related to health care services to enrollees or insureds, to comply with specified requirements. [HSC §1367.01 and INS §10123.135]
- Establishes as California's essential health benefits (EHBs) benchmark under the Patient protection and Affordable Care Act (ACA), the Kaiser Small Group Health Maintenance Organization, existing California health insurance mandates, and the 10 ACA mandated benefits, including prescription drug coverage. [HSC §1367.005 and INS §10112.27]
- Requires every health plan contract and insurance policy that provides hospital, medical, or surgical coverage to provide coverage for medically necessary treatment of mental health and SUDs under the same terms and conditions applied to other medical conditions, as specified. [HSC §1374.72 and INS §10144.5]
- Requires the health plan or insurer, if services for the medically necessary treatment of a mental health or SUD are not available in network within the geographic and timely access standards set by law or regulation, to arrange coverage to ensure the delivery of medically necessary out-of-network services and any medically necessary follow-up services that, to the maximum extent possible, meet those geographic and timely access standards. Includes, but is not limited to, providing services to secure medically necessary out-of-network options that are available to the enrollee within geographic and timely access standards, and requires the enrollee or insured to pay no more than the same cost sharing that would be paid for the same covered services received from an in-network provider. [HSC §1374.72 and INS §10144.5]
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, there is an urgent need to expand access to rapid initiation of medications to treat addiction. This bill expands on the recent work of the federal government to mainstream addiction treatment by eliminating unnecessary barriers to treatment. As a policy, commercially insured Californians are the only group where prior authorization delays are still allowed. The author concludes that by removing this last barrier this bill will expand low barrier treatment options for at risk patients, prevent overdose and save lives.
- BACKGROUND. This bill prohibits health plans and insurance policies from requiring prior authorization for buprenorphine products, methadone, or long-acting injectable naltrexone for detoxification (medically supervised withdrawal) or maintenance treatment of a SUD that is prescribed according to generally accepted national professional guidelines for the treatment of an SUD. According to the California Health Benefits Review Program (CHBRP), the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defines opioid use disorder (OUD) as “a problematic pattern of opioid use leading to clinically significant impairment or distress” and persons must meet at least two of the defined criteria within a 12-month period to receive a diagnosis. OUD applies to the class of medications or drugs that includes illegal drugs such as heroin, synthetic opioids such as fentanyl, and prescription pain medications such as oxycodone, hydrocodone, codeine, and morphine that are misused for indications other than prescribed. Prescription opioids are used to treat moderate to severe pain, and persons who take prescription opioids can develop opioid use disorder.
The DSM-5 characterizes alcohol use disorder as a pattern of alcohol use (e.g., wine, beer, and spirits) that results in significant impairment or distress. People meeting at least two of 11 specified criteria within a 12-month period are diagnosed with mild, moderate, or severe alcohol use disorder depending on the number of criteria met.
OUD prevalence in California was 1.58% among people aged 12 years and older in 2021. In the United States, among those reporting a prescription opioid use disorder, 35.2% also report alcohol use disorder. Alcohol use disorder prevalence in California was 11% among people aged 12 or older in 2021. In the United States, among those reporting alcohol use disorder, 3.9% report a related prescription opioid use disorder. In 2017, the U.S. Surgeon General declared the opioid crisis a U.S. public health emergency due to the escalating rates of opioid overdose, and related mortality and other harms. In addition to a greater risk of mortality and premature mortality, people with opioid use disorder are at a higher risk for developing cardiac dysrhythmias; respiratory depression; impairment in daily function; and contraction of infections including HIV, hepatitis (A, B, and C), tuberculosis, and endocarditis, which lead to increased use of health care services to treat those conditions.
The Substance Abuse and Mental Health Services Administration (SAMHSA) describes maintenance treatment as “providing medications to achieve and sustain clinical remission of signs and symptoms of OUD and support the individual process of recovery without a specific endpoint.” Some persons with OUD may require long-term medication treatment to ensure sustained recovery. There is evidence that relapse of OUD occurs less often for patients on medications (buprenorphine-naloxone and long-acting injectable naltrexone) for treatment (16%) compared to patients with no medication for treatment (40%). Some persons with alcohol use disorder experience a chronic condition with recurring treatment, abstinence, and relapse. Data from a nationally representative sample from 2012 to 2013 found that one third of adults with alcohol use disorder prior to the past year still had persistent alcohol use disorder, over half had remission from alcohol use disorder as classified by the DSM-5, and of the respondents that met criteria for remission, one third were indicative of recovery.
- Opioid Related Overdose Deaths in California. The Department of Public Health reports on its Opioid Overdose Death Dashboard that in 2021, there were 7,175 opioid related deaths in California. Of those over 83% involved fentanyl, a potent synthetic opioid drug that is approximately 50 times stronger than heroin and 100 times stronger than morphine. The number of deaths each year involving fentanyl increased dramatically between 2012 and 2021. During this time period fentanyl related overdose deaths increased by more than 7,250% -- from 82 deaths to 5,961 deaths in 2021.
In 2019, almost one third of white persons with opioid use disorder received medications for treatment compared to 20% of Black or other non-Latino multiracial groups and 15% of Latino persons. Prescribing practices changed significantly for medications prescribed for OUD (buprenorphine and long-acting injectable naltrexone) after the beginning of the COVID-19 pandemic, with 30.5% decrease for buprenorphine and 10.5% decrease of long-acting injectable naltrexone across all races/ethnicities. However, Black, Latino, and Asian persons experienced greater decreases in buprenorphine prescription fills compared to white persons. Racial disparities in overdoses have emerged with greater increases among Black and Latino persons. In California, the opioid-related overdose death rate was highest among American Indian/Alaskan Native and Black persons compared to white persons and healthcare utilization for opioid-related overdoses in the emergency department and hospitalization was highest among Black persons during 2021.
- Medication-assisted treatment (MAT). Treatments for SUD include prescription medication (medications for OUD or medications for alcohol use disorder), also called, MAT, as well as counseling, residential facilities, and mutual help groups (e.g., Alcoholics Anonymous, Narcotics Anonymous). This bill lists three U.S. Food and Drug Administration (FDA)-approved MAT options for OUD and alcohol use disorder: buprenorphine products, methadone, or long-acting injectable naltrexone. Methadone as a treatment for OUD is only available from opioid treatment programs (OTPs). Rules governing OTPs exist at both the federal and state levels: The federal government establishes baseline requirements for OTPs, and states layer additional requirements on top of them. The American Society of Addiction Medicine (ASAM) provides the National Practice Guidelines for the Use of Medications in the Treatment of Addiction Involving Opioid Use and SAMHSA provides the Treatment Improvement Protocol that reviews the clinical standards of care for patients with OUD including buprenorphine, methadone, and long-acting injectable naltrexone. In 2020, the ASAM updated requirements to include that all FDA approved medication prescribed for the treatment of OUD should be available to all persons seeking treatment.
- State programs. In 2017, California received more than $476 million in discretionary grants from SAMHSA to aid in the opioid crisis. The California Department of Health Care Services (DHCS) initiated the California MAT Expansion Program in response to the opioid epidemic in the state and to help stop overdose deaths. The goals of the program are to increase access to MAT, reduce unmet treatment need, and reduce opioid-related overdose deaths. The program targets populations who do not have access to medication including youth, people in rural areas, and American Indians and Alaska Native tribal communities. The program supports more than 30 projects in the state with 650 access points for treatment including more than 140,000 new Californians with opioid disorder who received medication through this program.
At least 18 states have laws that limit prior authorization on medications used to treat SUDs, as does the District of Columbia. The federal Consolidated Appropriations Act of 2023 removed the federal requirement that providers submit a Notice of Intent (waiver) to prescribe buprenorphine for OUD treatment. This legislation also removed the limits on the number of patients a practitioner may treat. This allows providers with a current Drug Enforcement Administration (DEA) registration with Schedule III authority to prescribe buprenorphine for OUD treatment as allowed by scope of practice in each state. With the removal of this waiver requirement, more providers are now able to prescribe buprenorphine.
- CHBRP analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP states the following in its analysis of this bill:
- Enrollees covered. The medications addressed by this bill are most commonly covered through a pharmacy benefit. For Medi-Cal beneficiaries in DMHC-regulated managed care plans, the pharmacy benefit is separate and is administered by DHCS. Therefore, these beneficiaries have a pharmacy benefit that is not subject to DMHC regulation. Among commercial/CalPERS enrollees, 1.2% do not have a pharmacy benefit and 3.2% have a pharmacy benefit that is not regulated by DMHC or CDI. Since this bill does not require coverage of the medications it addresses, baseline benefit coverage for enrollees without a pharmacy benefit or whose pharmacy benefit is not regulated by DMHC or CDI is compliant and would not change. Approximately 95.6% of commercial/CalPERS enrollees in plans and policies regulated by DMHC or CDI have a pharmacy benefit regulated by DMHC or CDI that would be subject to this bill. CHBRP estimates that 1% to 5% of these enrollees (the figure varies by medication) have a prior authorization requirement that would be prohibited by this bill. Postmandate, none of these enrollees would have a prior authorization requirement applicable to these medications when they are on formulary.
- Impact on utilization and expenditures. According to CHBRP, no measurable change in utilization or expenditures at the state level is expected because benefit coverage would change for very few commercial/CalPERS enrollees (1% to 5% of depending on the medication) and few in that group would both have one of the disorders and be a likely user of one of the medications. However, it is possible that a few enrollees might increase utilization of the medications addressed by this bill, postmandate.
- EHBs. This bill would not require coverage for a new state benefit mandate and would not appear to exceed the definition of EHBs in California.
- Medical effectiveness. There is limited evidence that removal of prior authorization requirements for buprenorphine products is associated with increased use and higher treatment retention for OUD. There is insufficient evidence on the impact of prior authorization on methadone use for OUD. There is insufficient evidence on the impact of prior authorization on long-acting injectable naltrexone use for either OUD or alcohol use disorder. For treatment of OUD, there is clear and convincing evidence that buprenorphine products and methadone are more effective with regard to treatment retention, reduction in use of illicit opioids, relapse, and improved health outcomes, compared to a placebo or no treatment. There is a preponderance of evidence that long-acting injectable naltrexone is effective with regard to treatment retention and abstinence, but not for overdose prevention, compared to a placebo or oral naltrexone. For treatment of alcohol use disorder, there is a preponderance of evidence that long-acting injectable naltrexone is more effective with regard to reducing return to drinking compared to a placebo or oral naltrexone.
- Public Health. CHBRP projects no measurable public health impact at the population level because this bill is not expected to create measurable changes in benefit coverage for or utilization at the state level. However, it is possible that this bill could yield some person-level health improvements if some enrollees increase utilization of the medications this bill addresses.
- Long-Term Impacts. Since the change in benefit coverage is so limited, no state-level long-term impacts of this bill on health outcomes, including premature death associated with OUD and alcohol use disorder, can be projected. However, if some enrollees increase utilization of the medications addressed by this bill, it is possible that there could be some reduction in premature deaths at the person level.
- CHBRP analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP states the following in its analysis of this bill:
- SUPPORT. National Health Law Program (NHLP) writes that for the past several years, California has made concerted efforts to increase access to MAT. One of these efforts has been ensuring that health plans across the state provide comprehensive coverage for all FDA-approved medications to treat OUD. As a result, both Medi-Cal and private health plans now offer coverage for methadone, buprenorphine, and naltrexone, as well as for services associated with effective use of these medications, such as ordering, prescribing, administering, and counseling. Despite these gains, however, many private plans continue to sidestep their responsibility to cover MAT by imposing utilization controls that only serve to reduce the costs to the plan, while establishing barriers to care and putting the lives of people with OUD at risk. The most commonly used of these utilization control techniques is prior authorization, an onerous requirement that delays access to lifesaving services without any significant benefit to the patient. Imposing prior authorization on MAT may also represent a violation of federal behavioral health parity requirements if it is applied disproportionately to MAT and other SUD treatment over physical health services. Given how beneficial MAT is for patients with OUD, California must ensure that patients can access the service without delay. NHLP states that prohibiting plans from imposing prior authorization is an important and essential step in that direction.
- OPPOSITION. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. All ACA-compliant plans provide a robust package of EHBs in the large group, small business, and individual markets (both on and off the Exchange). In the individual market, the ACA sought to preserve the balance between comprehensive coverage and affordability by requiring states to bear the cost for new mandates that exceed the EHB package. The Centers for Medicaid and Medicare Services recently affirmed that states are still responsible for defraying the cost of new mandates. The opposition states mandate bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options.
- RELATED LEGISLATION. AB 1060 (Ortega) requires coverage and prohibits cost sharing for prescription or nonprescription naloxone hydrochloride. AB 1060 is pending in Assembly Health Committee.
- PREVIOUS LEGISLATION.
- SB 854 (Jim Beall) of 2020 would have required health plan contracts and health insurance policies issued, amended, or renewed on or after January 1, 2021, that provide outpatient prescription drug benefits to cover all medically necessary prescription drugs approved by the United States Food and Drug Administration (FDA) for treating SUDs that are appropriate for the specific needs of an enrollee or insured. Would have required those drugs to be placed on the lowest cost-sharing tier of the plan or insurer’s prescription drug formulary, unless specified criteria are met. Would have prohibited prior authorization or step therapy requirements on a prescription drug approved by the FDA for treating SUDs, unless specified criteria are met. SB 854 was never heard in Senate Health Committee.
- AB 2384 (Arambula) of 2018 would have required a health insurer or a health care service plan, not including a Medi-Cal managed care plan, to cover, at a minimum, at least one version of each specified MAT, relapse prevention, and overdose reversal prescription drug approved by the FDA for OUD. Provides that at least one version of each MAT, relapse prevention, and overdose reversal prescription drug is not subject to specified requirements of a health plan or policy of health insurance, including prior authorization and an annual or lifetime dollar limit, as specified. Specifies that its provisions would apply to an FDA-approved drug for use in MAT for OUD, relapse prevention, or overdose reversal that an enrollee or insured is being prescribed as of January 1, 2019, or, for a new enrollee or insured, that he or she is being prescribed at the time of enrollment. Governor Brown vetoed this bill with the following message:
“This bill requires health plans to cover at least one version of each drug used in medication-assisted treatment for opioid disorders and restricts health plans' ability to manage the utilization of these drugs.
While the drugs specified in this bill are useful to treat opioid addiction, I'm not willing to eliminate requirements that may be in the best interest of patients.”
REGISTERED SUPPORT / OPPOSITION:
Support
Alkermes, INC.
California Academy of Family Physicians
California Life Sciences
California Society of Addiction Medicine
National Health Law Program
Opposition
America's Health Insurance Plans (AHIP)
Association of California Life & Health Insurance Companies
California Association of Health Plans
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
Discussed in Hearing
Assembly Floor
Senate Floor
Senate Standing Committee on Appropriations
Senate Standing Committee on Health
Assembly Floor
Assembly Standing Committee on Appropriations
Assembly Standing Committee on Health
Bill Author
Bill Co-Author(s):